ProShare Advisors LLC lifted its holdings in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 41.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,286 shares of the company's stock after acquiring an additional 16,409 shares during the quarter. ProShare Advisors LLC's holdings in Option Care Health were worth $1,306,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in Option Care Health by 29.6% during the 4th quarter. JPMorgan Chase & Co. now owns 1,511,403 shares of the company's stock worth $35,065,000 after buying an additional 344,875 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in Option Care Health by 7.8% during the 4th quarter. MetLife Investment Management LLC now owns 197,219 shares of the company's stock worth $4,575,000 after buying an additional 14,311 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Option Care Health by 6.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company's stock worth $58,235,000 after buying an additional 147,054 shares in the last quarter. Global Alpha Capital Management Ltd. lifted its holdings in Option Care Health by 38.1% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company's stock worth $1,596,000 after buying an additional 18,992 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Option Care Health during the 4th quarter worth $327,000. 98.05% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In other news, insider Michael Bavaro sold 30,996 shares of the stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the transaction, the insider now directly owns 44,974 shares in the company, valued at $1,495,835.24. This represents a 40.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.64% of the company's stock.
Analyst Ratings Changes
Several research analysts have issued reports on the company. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. JPMorgan Chase & Co. upped their target price on shares of Option Care Health from $40.00 to $41.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. JMP Securities reiterated a "market outperform" rating and set a $36.00 target price on shares of Option Care Health in a research report on Tuesday, April 22nd. Finally, Barrington Research reiterated an "outperform" rating and set a $38.00 target price on shares of Option Care Health in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Option Care Health has an average rating of "Moderate Buy" and an average target price of $35.50.
Read Our Latest Analysis on OPCH
Option Care Health Trading Up 2.0%
Shares of OPCH traded up $0.62 during trading hours on Tuesday, reaching $32.03. The stock had a trading volume of 119,867 shares, compared to its average volume of 1,856,091. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $35.53. The firm has a 50-day moving average of $32.93 and a 200 day moving average of $29.45. The company has a market cap of $5.24 billion, a P/E ratio of 26.98, a P/E/G ratio of 2.30 and a beta of 0.76.
Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. The firm had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.26 billion. Option Care Health had a net margin of 4.37% and a return on equity of 15.30%. The company's revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.26 EPS. On average, sell-side analysts expect that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.
Option Care Health Company Profile
(
Free Report)
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
Featured Stories

Before you consider Option Care Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Option Care Health wasn't on the list.
While Option Care Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.